Skip to content
Industry
This is research, not advice. We’re not SEBI-registered.

agilon health share price today

agilon health, inc. · AGL · Healthcare · Medical Care Facilities · price as of the 4 November 2026 close, updated every trading day · results updated weekly · All US stock lists

agilon health share price: $96.23 at the close on 4 November 2026, +476.9% in a year.

$96.23Price +476.9% in a year
$1.5 BRevenue (Jun 2026) +7.2% on a year ago
$18.0 MProfit (Jun 2026)
1.3%Operating margin +9.6 points on a year ago
−309%ROE FY25
−21.3%ROIC against a 21.3% cost of capital: −42.6 points

agilon health, inc.'s share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer.

Biggest thing to watch: the price has already been rising for 13 weeks, so timing is the risk more than the business.

The price has been rising for 13 weeks. Over the last four quarters, results have been improving. What will decide it: the next one or two quarters of results.

What is the agilon health share price today?

agilon health, inc.'s share price was $96.23 at the close on 4 November 2026. It has been rising for 13 weeks. That is 45.9% above its average price over the last 200 trading days. In the last 52 weeks it traded between $9 and $130, and at that close it sat 72% of the way up from that low.

A share price tends to move through four phases: moving sideways (stage 1), rising (stage 2), stalling near a high (stage 3) and falling (stage 4). Today agilon health, inc. is in stage 2. The phase helps read everything below.

Over the past 13 weeks it has done better than the S&P 500, and it has stayed ahead for 1 week in a row.

1Y

Nov 2026: $96.23, 45.9% above its 200-day average. The price has been rising for 13 weeks.

  • Price $96.23
  • 50-day avg $87.55
  • 200-day avg $65.97
Nov 2026: $96.23, 45.9% above its 200-day average. The price has been rising for 13 weeks.
WeekPrice50-day avg200-day avg
31 Oct 2025$19.91$27.06$63.19
7 Nov 2025$16.68$25.63$61.56
14 Nov 2025$14.40$24.09$59.76
21 Nov 2025$15.54$22.62$57.98
28 Nov 2025$16.28$21.64$56.60
5 Dec 2025$16.30$20.50$54.82
12 Dec 2025$17.98$19.57$53.07
19 Dec 2025$18.36$18.58$51.46
26 Dec 2025$18.14$18.11$49.95
2 Jan 2026$16.84$17.59$48.23
9 Jan 2026$24.80$17.31$46.01
16 Jan 2026$25.50$17.78$43.87
23 Jan 2026$24.77$18.36$42.31
30 Jan 2026$20.80$19.04$39.43
6 Feb 2026$16.20$19.39$36.98
13 Feb 2026$9.03$18.86$34.84
20 Feb 2026$10.94$18.27$32.98
27 Feb 2026$14.73$17.81$31.17
6 Mar 2026$14.96$17.63$29.98
13 Mar 2026$15.00$17.36$28.92
20 Mar 2026$10.66$16.89$27.84
27 Mar 2026$9.90$15.53$26.73
2 Apr 2026$10.74$14.27$25.81
10 Apr 2026$19.02$13.71$24.90
17 Apr 2026$30.05$14.37$24.13
24 Apr 2026$26.21$15.68$23.32
1 May 2026$29.58$17.52$22.62
8 May 2026$54.23$20.27$22.24
15 May 2026$81.73$25.93$22.80
22 May 2026$86.39$32.88$24.03
29 May 2026$92.28$38.84$25.38
5 Jun 2026$96.85$46.82$26.94
12 Jun 2026$112.91$56.48$28.78
18 Jun 2026$113.80$64.21$30.38
26 Jun 2026$119.25$73.18$32.41
2 Jul 2026$111.01$79.80$34.09
10 Jul 2026$114.85$88.27$36.16
17 Jul 2026$129.84$97.76$38.54
24 Jul 2026$98.00$103.65$40.70
31 Jul 2026$91.61$105.07$42.47
7 Aug 2026$95.51$106.19$44.25
14 Aug 2026$96.90$106.40$45.93
21 Aug 2026$96.58$106.08$47.79
28 Aug 2026$92.54$104.30$49.71
4 Sep 2026$88.50$101.99$51.53
11 Sep 2026$89.77$100.27$53.09
18 Sep 2026$89.16$98.25$54.95
25 Sep 2026$80.73$94.60$56.60
2 Oct 2026$84.14$90.71$58.19
9 Oct 2026$82.39$89.42$59.86
16 Oct 2026$85.12$88.57$61.57
23 Oct 2026$89.71$88.52$63.37
30 Oct 2026$84.90$87.87$64.99
4 Nov 2026$96.23$87.55$65.97
Weekly closing price ($) with its 50-day and 200-day averages. The strip under the chart shows the phase: tan sideways, green rising, yellow stalling near a high, orange falling. 1-year window.

3Y

Nov 2026: $96.23, 45.9% above its 200-day average. The price has been rising for 13 weeks.

  • Price $96.23
  • 50-day avg $87.55
  • 200-day avg $65.97
Nov 2026: $96.23, 45.9% above its 200-day average. The price has been rising for 13 weeks.
WeekPrice50-day avg200-day avg
3 Nov 2023$366.50$454.15$519.95
10 Nov 2023$283.00$441.45$515.13
17 Nov 2023$298.50$426.13$509.04
24 Nov 2023$295.00$413.03$503.84
1 Dec 2023$282.00$394.79$496.33
8 Dec 2023$288.75$376.57$489.35
15 Dec 2023$327.00$363.30$483.61
22 Dec 2023$311.50$348.90$476.22
29 Dec 2023$313.75$335.96$470.80
5 Jan 2024$215.75$320.56$463.07
12 Jan 2024$184.50$295.80$450.60
19 Jan 2024$159.25$278.96$441.67
26 Jan 2024$145.50$264.36$429.13
2 Feb 2024$152.00$249.22$415.39
9 Feb 2024$170.50$236.53$403.58
16 Feb 2024$177.75$227.03$392.88
23 Feb 2024$156.75$217.09$383.78
1 Mar 2024$151.00$200.56$372.16
8 Mar 2024$148.00$183.88$361.92
15 Mar 2024$133.00$166.34$352.70
22 Mar 2024$122.25$156.53$343.44
28 Mar 2024$152.50$152.28$335.72
5 Apr 2024$118.75$148.50$327.24
12 Apr 2024$123.75$147.12$320.01
19 Apr 2024$136.50$144.32$312.35
26 Apr 2024$125.00$139.54$304.98
3 May 2024$120.75$135.32$297.41
10 May 2024$129.75$132.34$289.06
17 May 2024$135.25$130.95$280.63
24 May 2024$152.25$131.18$271.95
31 May 2024$157.50$132.54$265.66
7 Jun 2024$170.00$136.15$258.86
14 Jun 2024$172.50$139.88$252.40
21 Jun 2024$163.00$142.56$246.76
28 Jun 2024$163.50$146.68$239.42
5 Jul 2024$149.00$147.96$233.24
12 Jul 2024$157.25$149.85$225.52
19 Jul 2024$172.25$155.26$218.49
26 Jul 2024$172.25$159.31$211.49
2 Aug 2024$158.50$162.84$204.24
9 Aug 2024$138.00$162.76$195.80
16 Aug 2024$121.25$159.69$187.61
23 Aug 2024$112.00$154.21$180.53
30 Aug 2024$102.00$147.94$175.59
6 Sep 2024$90.25$142.87$171.50
13 Sep 2024$88.25$135.79$166.40
20 Sep 2024$88.00$130.17$161.78
27 Sep 2024$93.50$122.25$157.06
4 Oct 2024$80.25$113.80$151.22
11 Oct 2024$80.50$104.38$145.34
18 Oct 2024$74.50$97.42$139.55
25 Oct 2024$64.50$90.98$135.46
1 Nov 2024$67.50$85.81$132.48
8 Nov 2024$46.00$81.56$130.11
15 Nov 2024$39.50$76.27$127.58
22 Nov 2024$47.25$72.06$124.71
29 Nov 2024$52.25$68.92$122.22
6 Dec 2024$54.25$65.14$119.39
13 Dec 2024$56.00$61.50$116.81
20 Dec 2024$49.25$58.52$114.34
27 Dec 2024$47.50$55.65$112.42
3 Jan 2025$52.25$53.60$110.72
10 Jan 2025$60.75$52.69$109.25
17 Jan 2025$77.25$53.48$107.59
24 Jan 2025$90.25$55.49$106.93
31 Jan 2025$83.50$59.52$105.88
7 Feb 2025$83.25$63.77$104.81
14 Feb 2025$85.50$66.95$103.72
21 Feb 2025$88.00$69.66$102.98
28 Feb 2025$78.00$72.81$101.93
7 Mar 2025$87.75$76.19$100.65
14 Mar 2025$101.25$81.16$99.50
21 Mar 2025$113.25$86.88$98.34
28 Mar 2025$112.25$91.63$97.00
4 Apr 2025$103.75$93.59$95.32
11 Apr 2025$142.00$97.81$94.52
17 Apr 2025$100.00$101.26$93.88
25 Apr 2025$97.50$102.72$92.65
2 May 2025$104.00$103.95$91.14
9 May 2025$72.25$104.24$88.98
16 May 2025$61.25$102.74$86.30
23 May 2025$55.50$99.10$83.69
30 May 2025$55.50$95.13$82.05
6 Jun 2025$54.00$89.56$80.27
13 Jun 2025$53.75$84.36$78.85
20 Jun 2025$52.75$79.77$77.84
27 Jun 2025$57.75$71.61$76.84
3 Jul 2025$60.75$67.53$76.35
11 Jul 2025$55.75$63.66$75.50
18 Jul 2025$53.00$58.65$74.52
25 Jul 2025$51.50$56.44$73.67
1 Aug 2025$42.50$54.85$72.83
8 Aug 2025$21.84$51.84$71.46
15 Aug 2025$27.75$48.75$70.38
22 Aug 2025$33.25$46.32$69.54
29 Aug 2025$32.00$44.15$68.74
5 Sep 2025$30.00$42.26$68.40
12 Sep 2025$26.75$39.26$68.08
19 Sep 2025$29.00$36.24$67.50
26 Sep 2025$27.25$33.52$66.81
3 Oct 2025$28.25$30.79$66.13
10 Oct 2025$23.66$28.57$65.54
17 Oct 2025$24.00$27.87$64.95
24 Oct 2025$24.25$27.91$64.29
31 Oct 2025$19.91$27.06$63.19
7 Nov 2025$16.68$25.63$61.56
14 Nov 2025$14.40$24.09$59.76
21 Nov 2025$15.54$22.62$57.98
28 Nov 2025$16.28$21.64$56.60
5 Dec 2025$16.30$20.50$54.82
12 Dec 2025$17.98$19.57$53.07
19 Dec 2025$18.36$18.58$51.46
26 Dec 2025$18.14$18.11$49.95
2 Jan 2026$16.84$17.59$48.23
9 Jan 2026$24.80$17.31$46.01
16 Jan 2026$25.50$17.78$43.87
23 Jan 2026$24.77$18.36$42.31
30 Jan 2026$20.80$19.04$39.43
6 Feb 2026$16.20$19.39$36.98
13 Feb 2026$9.03$18.86$34.84
20 Feb 2026$10.94$18.27$32.98
27 Feb 2026$14.73$17.81$31.17
6 Mar 2026$14.96$17.63$29.98
13 Mar 2026$15.00$17.36$28.92
20 Mar 2026$10.66$16.89$27.84
27 Mar 2026$9.90$15.53$26.73
2 Apr 2026$10.74$14.27$25.81
10 Apr 2026$19.02$13.71$24.90
17 Apr 2026$30.05$14.37$24.13
24 Apr 2026$26.21$15.68$23.32
1 May 2026$29.58$17.52$22.62
8 May 2026$54.23$20.27$22.24
15 May 2026$81.73$25.93$22.80
22 May 2026$86.39$32.88$24.03
29 May 2026$92.28$38.84$25.38
5 Jun 2026$96.85$46.82$26.94
12 Jun 2026$112.91$56.48$28.78
18 Jun 2026$113.80$64.21$30.38
26 Jun 2026$119.25$73.18$32.41
2 Jul 2026$111.01$79.80$34.09
10 Jul 2026$114.85$88.27$36.16
17 Jul 2026$129.84$97.76$38.54
24 Jul 2026$98.00$103.65$40.70
31 Jul 2026$91.61$105.07$42.47
7 Aug 2026$95.51$106.19$44.25
14 Aug 2026$96.90$106.40$45.93
21 Aug 2026$96.58$106.08$47.79
28 Aug 2026$92.54$104.30$49.71
4 Sep 2026$88.50$101.99$51.53
11 Sep 2026$89.77$100.27$53.09
18 Sep 2026$89.16$98.25$54.95
25 Sep 2026$80.73$94.60$56.60
2 Oct 2026$84.14$90.71$58.19
9 Oct 2026$82.39$89.42$59.86
16 Oct 2026$85.12$88.57$61.57
23 Oct 2026$89.71$88.52$63.37
30 Oct 2026$84.90$87.87$64.99
4 Nov 2026$96.23$87.55$65.97
Weekly closing price ($) with its 50-day and 200-day averages. The strip under the chart shows the phase: tan sideways, green rising, yellow stalling near a high, orange falling. 3-year window.

5Y

Nov 2026: $96.23, 45.9% above its 200-day average. The price has been rising for 13 weeks.

  • Price $96.23
  • 50-day avg $87.55
  • 200-day avg $65.97
Nov 2026: $96.23, 45.9% above its 200-day average. The price has been rising for 13 weeks.
WeekPrice50-day avg200-day avg
29 Oct 2021$612.50$721.11–
12 Nov 2021$637.75$666.42–
26 Nov 2021$539.75$627.12–
10 Dec 2021$571.50$602.10–
23 Dec 2021$684.75$597.64–
7 Jan 2022$581.50$608.25–
21 Jan 2022$408.00$585.06–
4 Feb 2022$447.50$544.83$739.22
18 Feb 2022$489.50$535.92$724.96
4 Mar 2022$546.75$519.37$711.99
18 Mar 2022$587.50$491.27$694.14
1 Apr 2022$651.25$509.43$677.22
14 Apr 2022$576.75$545.18$658.34
29 Apr 2022$444.25$544.18$637.65
13 May 2022$479.25$534.93$614.64
27 May 2022$492.50$526.64$593.66
10 Jun 2022$490.25$507.56$576.33
24 Jun 2022$549.50$484.92$558.33
8 Jul 2022$667.50$494.81$550.49
22 Jul 2022$629.50$535.99$549.66
5 Aug 2022$639.75$570.09$550.90
19 Aug 2022$508.50$590.62$550.37
2 Sep 2022$526.75$598.91$545.41
16 Sep 2022$605.50$602.15$546.21
30 Sep 2022$585.50$586.65$546.68
14 Oct 2022$529.50$573.27$543.42
28 Oct 2022$503.00$554.28$538.05
11 Nov 2022$474.50$541.74$539.74
25 Nov 2022$416.50$514.50$539.17
9 Dec 2022$432.75$485.20$535.49
23 Dec 2022$407.00$455.44$530.91
6 Jan 2023$384.75$437.04$525.39
20 Jan 2023$510.25$436.76$519.34
3 Feb 2023$551.25$453.32$516.07
17 Feb 2023$569.75$481.42$520.68
3 Mar 2023$630.50$503.55$525.80
17 Mar 2023$667.50$543.76$532.19
31 Mar 2023$593.75$585.93$541.38
14 Apr 2023$711.50$613.04$548.48
28 Apr 2023$606.75$628.02$549.87
12 May 2023$603.75$640.87$548.30
26 May 2023$506.50$628.08$542.98
9 Jun 2023$519.25$595.27$540.95
23 Jun 2023$427.25$561.81$537.81
7 Jul 2023$413.50$518.89$530.00
21 Jul 2023$458.50$482.81$522.74
4 Aug 2023$486.75$462.14$518.21
18 Aug 2023$443.75$454.92$516.27
1 Sep 2023$445.00$446.88$514.85
15 Sep 2023$468.75$452.05$516.28
29 Sep 2023$444.00$457.81$517.30
13 Oct 2023$453.75$455.05$518.98
27 Oct 2023$451.50$454.88$521.72
10 Nov 2023$283.00$441.45$515.13
24 Nov 2023$295.00$413.03$503.84
8 Dec 2023$288.75$376.57$489.35
22 Dec 2023$311.50$348.90$476.22
5 Jan 2024$215.75$320.56$463.07
19 Jan 2024$159.25$278.96$441.67
2 Feb 2024$152.00$249.22$415.39
16 Feb 2024$177.75$227.03$392.88
1 Mar 2024$151.00$200.56$372.16
15 Mar 2024$133.00$166.34$352.70
28 Mar 2024$152.50$152.28$335.72
12 Apr 2024$123.75$147.12$320.01
26 Apr 2024$125.00$139.54$304.98
10 May 2024$129.75$132.34$289.06
24 May 2024$152.25$131.18$271.95
7 Jun 2024$170.00$136.15$258.86
21 Jun 2024$163.00$142.56$246.76
5 Jul 2024$149.00$147.96$233.24
19 Jul 2024$172.25$155.26$218.49
2 Aug 2024$158.50$162.84$204.24
16 Aug 2024$121.25$159.69$187.61
30 Aug 2024$102.00$147.94$175.59
13 Sep 2024$88.25$135.79$166.40
27 Sep 2024$93.50$122.25$157.06
11 Oct 2024$80.50$104.38$145.34
25 Oct 2024$64.50$90.98$135.46
8 Nov 2024$46.00$81.56$130.11
22 Nov 2024$47.25$72.06$124.71
6 Dec 2024$54.25$65.14$119.39
20 Dec 2024$49.25$58.52$114.34
3 Jan 2025$52.25$53.60$110.72
17 Jan 2025$77.25$53.48$107.59
31 Jan 2025$83.50$59.52$105.88
14 Feb 2025$85.50$66.95$103.72
28 Feb 2025$78.00$72.81$101.93
14 Mar 2025$101.25$81.16$99.50
28 Mar 2025$112.25$91.63$97.00
11 Apr 2025$142.00$97.81$94.52
25 Apr 2025$97.50$102.72$92.65
9 May 2025$72.25$104.24$88.98
23 May 2025$55.50$99.10$83.69
6 Jun 2025$54.00$89.56$80.27
20 Jun 2025$52.75$79.77$77.84
3 Jul 2025$60.75$67.53$76.35
18 Jul 2025$53.00$58.65$74.52
1 Aug 2025$42.50$54.85$72.83
15 Aug 2025$27.75$48.75$70.38
29 Aug 2025$32.00$44.15$68.74
12 Sep 2025$26.75$39.26$68.08
26 Sep 2025$27.25$33.52$66.81
10 Oct 2025$23.66$28.57$65.54
24 Oct 2025$24.25$27.91$64.29
7 Nov 2025$16.68$25.63$61.56
21 Nov 2025$15.54$22.62$57.98
5 Dec 2025$16.30$20.50$54.82
19 Dec 2025$18.36$18.58$51.46
2 Jan 2026$16.84$17.59$48.23
16 Jan 2026$25.50$17.78$43.87
30 Jan 2026$20.80$19.04$39.43
13 Feb 2026$9.03$18.86$34.84
27 Feb 2026$14.73$17.81$31.17
13 Mar 2026$15.00$17.36$28.92
27 Mar 2026$9.90$15.53$26.73
10 Apr 2026$19.02$13.71$24.90
24 Apr 2026$26.21$15.68$23.32
8 May 2026$54.23$20.27$22.24
22 May 2026$86.39$32.88$24.03
5 Jun 2026$96.85$46.82$26.94
18 Jun 2026$113.80$64.21$30.38
2 Jul 2026$111.01$79.80$34.09
17 Jul 2026$129.84$97.76$38.54
31 Jul 2026$91.61$105.07$42.47
14 Aug 2026$96.90$106.40$45.93
28 Aug 2026$92.54$104.30$49.71
11 Sep 2026$89.77$100.27$53.09
25 Sep 2026$80.73$94.60$56.60
9 Oct 2026$82.39$89.42$59.86
23 Oct 2026$89.71$88.52$63.37
4 Nov 2026$96.23$87.55$65.97
Weekly closing price ($) with its 50-day and 200-day averages. The strip under the chart shows the phase: tan sideways, green rising, yellow stalling near a high, orange falling. 5-year window.

Price stage: Falling from Oct 2025 to Apr 2026; Sideways from Apr 2026 to Aug 2026; Rising from Aug 2026 to Nov 2026.

Price stage: Falling from Nov 2023 to Mar 2025; Sideways from Mar 2025 to May 2025; Falling from May 2025 to Apr 2026; Sideways from Apr 2026 to Aug 2026; Rising from Aug 2026 to Nov 2026.

Price stage: Sideways in Sep 2022; Falling from Oct 2022 to Jan 2023; Sideways from Feb 2023 to May 2023; Sideways from May 2023 to Jun 2023; Falling from Jul 2023 to Aug 2023; Sideways from Aug 2023 to Sep 2023; Falling from Sep 2023 to Feb 2025; Sideways from Mar 2025 to Apr 2025; Falling from May 2025 to Apr 2026; Sideways from Apr 2026 to Jul 2026; Rising from Aug 2026 to Nov 2026.

Week by week since 2021: did it beat the S&P 500 over the past 13 weeks?

Ahead in 102 of 278 weeks

Week by week since 2021: did it beat the S&P 500 over the past 13 weeks?
Week13-week return vs S&P 500
16 Apr 2021no S&P 500 reading
23 Apr 2021no S&P 500 reading
30 Apr 2021no S&P 500 reading
7 May 2021no S&P 500 reading
14 May 2021no S&P 500 reading
21 May 2021no S&P 500 reading
28 May 2021no S&P 500 reading
4 Jun 2021no S&P 500 reading
11 Jun 2021no S&P 500 reading
18 Jun 2021no S&P 500 reading
25 Jun 2021no S&P 500 reading
2 Jul 2021no S&P 500 reading
9 Jul 2021no S&P 500 reading
16 Jul 2021+10.3%
23 Jul 2021+11.9%
30 Jul 2021+11.6%
6 Aug 2021+1.5%
13 Aug 2021+9.9%
20 Aug 2021−3.7%
27 Aug 2021−4.7%
3 Sep 2021−3.6%
10 Sep 2021−18.7%
17 Sep 2021−39.3%
24 Sep 2021−32.7%
1 Oct 2021−33.0%
8 Oct 2021−29.6%
15 Oct 2021−33.1%
22 Oct 2021−38.7%
29 Oct 2021−38.1%
5 Nov 2021−35.9%
12 Nov 2021−32.0%
19 Nov 2021−38.1%
26 Nov 2021−43.3%
3 Dec 2021−40.8%
10 Dec 2021−33.7%
17 Dec 2021−23.8%
23 Dec 2021−8.5%
31 Dec 2021−5.3%
7 Jan 2022−14.6%
14 Jan 2022−22.4%
21 Jan 2022−27.8%
28 Jan 2022−33.7%
4 Feb 2022−23.9%
11 Feb 2022−9.9%
18 Feb 2022−10.2%
25 Feb 2022−1.4%
4 Mar 2022+5.8%
11 Mar 2022+6.2%
18 Mar 2022+4.1%
25 Mar 2022−10.1%
1 Apr 2022+1.1%
8 Apr 2022+7.5%
14 Apr 2022+23.4%
22 Apr 2022+17.7%
29 Apr 2022+22.7%
6 May 2022+7.0%
13 May 2022−2.1%
20 May 2022+9.9%
27 May 2022+2.2%
3 Jun 2022−5.4%
10 Jun 2022−2.9%
17 Jun 2022−0.8%
24 Jun 2022+7.0%
1 Jul 2022+2.6%
8 Jul 2022+24.0%
15 Jul 2022+26.4%
22 Jul 2022+41.4%
29 Jul 2022+40.9%
5 Aug 2022+44.3%
12 Aug 2022+15.7%
19 Aug 2022−4.0%
26 Aug 2022+9.9%
2 Sep 2022+12.0%
9 Sep 2022+15.4%
16 Sep 2022+21.1%
23 Sep 2022+7.7%
30 Sep 2022+9.9%
7 Oct 2022−8.8%
14 Oct 2022−12.6%
21 Oct 2022−14.7%
28 Oct 2022−14.0%
4 Nov 2022−23.3%
11 Nov 2022−12.2%
18 Nov 2022−9.4%
25 Nov 2022−20.6%
2 Dec 2022−17.7%
9 Dec 2022−23.0%
16 Dec 2022−28.3%
23 Dec 2022−31.5%
30 Dec 2022−38.2%
6 Jan 2023−38.8%
13 Jan 2023−17.8%
20 Jan 2023−4.5%
27 Jan 2023−2.1%
3 Feb 2023+17.7%
10 Feb 2023+17.9%
17 Feb 2023+29.9%
24 Feb 2023+28.2%
3 Mar 2023+39.8%
10 Mar 2023+33.8%
17 Mar 2023+53.2%
24 Mar 2023+72.9%
31 Mar 2023+40.1%
6 Apr 2023+64.4%
14 Apr 2023+40.0%
21 Apr 2023+18.4%
28 Apr 2023+15.6%
5 May 2023+11.1%
12 May 2023+4.9%
19 May 2023−6.9%
26 May 2023−10.0%
2 Jun 2023−25.7%
9 Jun 2023−20.5%
16 Jun 2023−47.7%
23 Jun 2023−49.9%
30 Jun 2023−35.3%
7 Jul 2023−43.9%
14 Jul 2023−50.2%
21 Jul 2023−36.4%
28 Jul 2023−32.1%
4 Aug 2023−28.8%
11 Aug 2023−30.8%
18 Aug 2023−23.0%
25 Aug 2023−19.8%
1 Sep 2023−17.4%
8 Sep 2023−14.8%
15 Sep 2023+7.1%
22 Sep 2023+8.5%
29 Sep 2023+6.0%
6 Oct 2023+12.5%
13 Oct 2023+12.6%
20 Oct 2023+12.3%
27 Oct 2023+5.8%
3 Nov 2023−22.0%
10 Nov 2023−38.4%
17 Nov 2023−36.0%
24 Nov 2023−35.0%
1 Dec 2023−38.4%
8 Dec 2023−40.7%
15 Dec 2023−36.1%
22 Dec 2023−42.4%
29 Dec 2023−40.5%
5 Jan 2024−61.7%
12 Jan 2024−69.8%
19 Jan 2024−81.6%
26 Jan 2024−86.5%
2 Feb 2024−72.3%
9 Feb 2024−53.5%
16 Feb 2024−51.3%
23 Feb 2024−58.4%
1 Mar 2024−58.2%
8 Mar 2024−59.9%
15 Mar 2024−68.0%
22 Mar 2024−70.8%
28 Mar 2024−61.4%
5 Apr 2024−55.8%
12 Apr 2024−40.1%
19 Apr 2024−16.9%
26 Apr 2024−18.4%
3 May 2024−24.0%
10 May 2024−27.8%
17 May 2024−29.9%
24 May 2024−7.1%
31 May 2024+1.5%
7 Jun 2024+10.5%
14 Jun 2024+23.2%
21 Jun 2024+28.9%
28 Jun 2024+3.2%
5 Jul 2024+18.5%
12 Jul 2024+17.5%
19 Jul 2024+15.3%
26 Jul 2024+30.7%
2 Aug 2024+27.0%
9 Aug 2024+4.0%
16 Aug 2024−15.0%
23 Aug 2024−32.6%
30 Aug 2024−42.1%
6 Sep 2024−48.1%
13 Sep 2024−52.4%
20 Sep 2024−50.4%
27 Sep 2024−47.8%
4 Oct 2024−49.4%
11 Oct 2024−52.3%
18 Oct 2024−63.2%
25 Oct 2024−68.9%
1 Nov 2024−64.6%
8 Nov 2024−78.9%
15 Nov 2024−73.1%
22 Nov 2024−63.8%
29 Nov 2024−55.7%
6 Dec 2024−52.4%
13 Dec 2024−44.1%
20 Dec 2024−48.1%
27 Dec 2024−53.3%
3 Jan 2025−38.2%
10 Jan 2025−24.7%
17 Jan 2025+1.5%
24 Jan 2025+34.9%
31 Jan 2025+18.3%
7 Feb 2025+80.5%
14 Feb 2025+112.4%
21 Feb 2025+85.5%
28 Feb 2025+50.7%
7 Mar 2025+67.0%
14 Mar 2025+87.7%
21 Mar 2025+134.5%
28 Mar 2025+142.9%
4 Apr 2025+113.2%
11 Apr 2025+141.8%
17 Apr 2025+41.4%
25 Apr 2025+17.5%
2 May 2025+30.4%
9 May 2025−7.1%
16 May 2025−25.8%
23 May 2025−33.5%
30 May 2025−28.0%
6 Jun 2025−42.5%
13 Jun 2025−53.0%
20 Jun 2025−58.8%
27 Jun 2025−59.2%
3 Jul 2025−65.2%
11 Jul 2025−77.5%
18 Jul 2025−66.2%
25 Jul 2025−62.9%
1 Aug 2025−68.8%
8 Aug 2025−82.7%
15 Aug 2025−63.0%
22 Aug 2025−51.5%
29 Aug 2025−51.8%
5 Sep 2025−52.5%
12 Sep 2025−60.4%
19 Sep 2025−56.7%
26 Sep 2025−60.4%
3 Oct 2025−60.5%
10 Oct 2025−62.3%
17 Oct 2025−60.6%
24 Oct 2025−59.2%
31 Oct 2025−62.9%
7 Nov 2025−28.9%
14 Nov 2025−52.5%
21 Nov 2025−55.4%
28 Nov 2025−55.1%
5 Dec 2025−51.6%
12 Dec 2025−36.5%
19 Dec 2025−39.2%
26 Dec 2025−37.7%
2 Jan 2026−42.5%
9 Jan 2026−1.5%
16 Jan 2026+2.1%
23 Jan 2026+0.4%
30 Jan 2026+3.0%
6 Feb 2026−5.8%
13 Feb 2026−38.8%
20 Feb 2026−34.2%
27 Feb 2026−9.9%
6 Mar 2026−6.3%
13 Mar 2026−13.7%
20 Mar 2026−37.2%
27 Mar 2026−37.3%
2 Apr 2026−32.2%
10 Apr 2026−21.2%
17 Apr 2026+15.2%
24 Apr 2026+2.2%
1 May 2026+38.1%
8 May 2026+227.9%
15 May 2026+796.7%
22 May 2026+681.5%
29 May 2026+516.2%
5 Jun 2026+537.7%
12 Jun 2026+640.7%
18 Jun 2026+952.4%
26 Jun 2026+1089.6%
2 Jul 2026+920.0%
10 Jul 2026+492.7%
17 Jul 2026+327.4%
24 Jul 2026+270.4%
31 Jul 2026+206.0%
7 Aug 2026+71.3%
14 Aug 2026+13.5%
21 Aug 2026+9.1%
28 Aug 2026−1.4%
4 Sep 2026−13.0%
11 Sep 2026−23.5%
18 Sep 2026−23.7%
25 Sep 2026−38.1%
2 Oct 2026−27.5%
9 Oct 2026−31.4%
16 Oct 2026−37.1%
23 Oct 2026−11.3%
30 Oct 2026−8.5%
4 Nov 2026+1.6%
Each bar is one week, from 2021 to now (278 weeks with a reading). Green means the stock's return over the previous 13 weeks beat the S&P 500; red means it trailed. The colour is strongest at a gap of 25 percentage points or more. A gap means there is no reading for that week.

Over the last 5.6 years the share price moved −87% while the S&P 500 moved +84%, so it is behind the index over that whole period. The chart above shows the 13-week comparison for every week.

This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row.

What dividend does agilon health pay?

agilon health, inc. pays no dividend. In the last 12 reported quarters it declared no dividend per share, so there is no payout history to chart and no yield to show. Companies like this usually keep their earnings in the business, so the cash-flow sections show where that cash goes.

Which stock lists is agilon health on?

agilon health is not in the Nasdaq 100, the S&P 500 or the Dow Jones 30, and is not on the US tech stocks list.

Is agilon health profitable?

agilon health, inc. earned $18.0 M of net profit in the Jun 2026 quarter. The full FY25 year was a loss of $391 M. That is 1.2% of the quarter's revenue. The same quarter a year earlier lost $104 M. 9 of the last 12 reported quarters were loss-making.

Net profit is what is left after every cost, interest and tax. Earnings per share, dividends and book value all grow from it.

FY25 profit −$391 M

  • Net profit −$391 M
FY25 profit −$391 M
QuarterNet profit
FY21−$407 M
FY22−$107 M
FY23−$263 M
FY24−$260 M
FY25−$391 M
Net profit each year, $ M. 5-year window. A grey bar is lower than the year before.

Jun 2026: $18.0 M

  • Net profit (quarterly) $18.0 M
Jun 2026: $18.0 M
QuarterNet profit (quarterly)
Sep 2023−$31.5 M
Dec 2023−$230 M
Mar 2024−$6.0 M
Jun 2024−$30.7 M
Sep 2024−$118 M
Dec 2024−$106 M
Mar 2025$12.1 M
Jun 2025−$104 M
Sep 2025−$110 M
Dec 2025−$189 M
Mar 2026$48.9 M
Jun 2026$18.0 M

Growth on a year earlier

  • Growth on a year earlier 303.9%
Growth on a year earlier
QuarterGrowth on a year earlier
Sep 2023–
Dec 2023–
Mar 2024−137.8%
Jun 2024–
Sep 2024–
Dec 2024–
Mar 2025–
Jun 2025–
Sep 2025–
Dec 2025–
Mar 2026303.9%
Jun 2026–
Top: net profit each quarter, $ M. Below: growth on the same quarter a year earlier, %. Last 12 quarters. A grey bar is lower than the quarter before.

How much revenue does agilon health make, and is it growing?

agilon health, inc. reported $1.5 B of revenue in the Jun 2026 quarter, +7.2% on the same quarter a year earlier. Over 4 years it has grown 40.5% a year on average. The last full year, FY25, came in at $5.9 B. The last four reported quarters add to $5.9 B.

Revenue is everything the company billed its customers in the period.

FY25 revenue was $5.9 B, −2.1% on the year before.

FY25 revenue $5.9 B (−2.1% on the year before), 40.5% a year over 4 years

  • Revenue $5.9 B
FY25 revenue $5.9 B (−2.1% on the year before), 40.5% a year over 4 years
QuarterRevenue
FY21$1.5 B
FY22$2.4 B
FY23$4.3 B
FY24$6.1 B
FY25$5.9 B

Growth on a year earlier

  • Growth on a year earlier −2.1%
Growth on a year earlier
QuarterGrowth on a year earlier
FY21–
FY2257%
FY2380.7%
FY2440.4%
FY25−2.1%
Top: revenue each year, $ B. Below: growth on the year before, %. 5-year window. A grey bar is lower than the year before.

Jun 2026: $1.5 B (+7.2% on a year earlier)

  • Revenue (quarterly) $1.5 B
Jun 2026: $1.5 B (+7.2% on a year earlier)
QuarterRevenue (quarterly)
Sep 2023$1.1 B
Dec 2023$1.1 B
Mar 2024$1.6 B
Jun 2024$1.5 B
Sep 2024$1.5 B
Dec 2024$1.5 B
Mar 2025$1.5 B
Jun 2025$1.4 B
Sep 2025$1.4 B
Dec 2025$1.6 B
Mar 2026$1.4 B
Jun 2026$1.5 B

Growth on a year earlier

  • Growth on a year earlier 7.2%
Growth on a year earlier
QuarterGrowth on a year earlier
Sep 202363.6%
Dec 2023–
Mar 202452.2%
Jun 202438.7%
Sep 202427.6%
Dec 202444.2%
Mar 2025−4.5%
Jun 2025−5.9%
Sep 2025−1.1%
Dec 20253.1%
Mar 2026−7.3%
Jun 20267.2%
Top: revenue each quarter, $ B. Below: growth on the same quarter a year earlier, %. Last 12 quarters. A grey bar is lower than the quarter before.

Recent pace: the last four quarters grew +0.5% on average, against 40.5% a year over the longer run, so this year is growing slower than its own long-run rate.

Is growth speeding up? Revenue over the last 12 months grew +0.3%, against +5.9% a year over the last 8 quarters (rolling over).

How much of every $100 of sales does agilon health keep?

agilon health, inc.'s operating margin was 1.3% in the Jun 2026 quarter, 9.6 percentage points higher than the same quarter a year ago. Across 5 years it has been between −24.1% and −4.3%. The latest quarter is above every full year in that period.

Operating margin is what is left from every $100 of sales after the costs of running the business, before interest and tax. It shows pricing power and cost control.

Why the margin moved: operating margin changed +9.6 percentage points on the year while gross margin changed +11.0 points. So the gain came mostly from the gross margin, which means input costs and prices charged.

FY25: −7.1%, within a range of −24.1% to −4.3% over 5 years

  • Operating margin −7.1%
FY25: −7.1%, within a range of −24.1% to −4.3% over 5 years
QuarterOperating margin
FY21−24.1%
FY22−4.3%
FY23−5.4%
FY24−4.7%
FY25−7.1%

Change on the year before (points)

  • Change on the year before (points) −2.4 pts
Change on the year before (points)
QuarterChange on the year before (points)
FY21–
FY22+19.8 pts
FY23−1.1 pts
FY24+0.7 pts
FY25−2.4 pts
Operating margin each year, % (top). Below: change on the year before, in percentage points. 5-year window.

Jun 2026: operating margin 1.3% (+9.6 points on a year earlier)

  • Operating margin 1.3%
Jun 2026: operating margin 1.3% (+9.6 points on a year earlier)
QuarterOperating margin
Sep 2023−3.5%
Dec 2023−15.6%
Mar 2024−0.3%
Jun 2024−2.9%
Sep 2024−9.1%
Dec 2024−6.9%
Mar 2025−1.4%
Jun 2025−8.3%
Sep 2025−8.9%
Dec 2025−10%
Mar 20260.7%
Jun 20261.3%

Change on a year earlier (points)

  • Change on a year earlier (points) +9.6 pts
Change on a year earlier (points)
QuarterChange on a year earlier (points)
Sep 2023+0.7 pts
Dec 2023–
Mar 2024−0.4 pts
Jun 2024−0.2 pts
Sep 2024−5.6 pts
Dec 2024+8.7 pts
Mar 2025−1.1 pts
Jun 2025−5.4 pts
Sep 2025+0.2 pts
Dec 2025−3.1 pts
Mar 2026+2.1 pts
Jun 2026+9.6 pts
Top: quarterly operating margin, %. Below: change on the same quarter a year earlier, in percentage points. Last 12 quarters. Operating profit as a share of revenue, each quarter.

Is agilon health's profit turning into cash?

agilon health, inc.'s cash-flow history is too short to judge how much of its profit turns into cash. In FY25 its operations used $106 M of cash, against −$391 M of profit. After $13.2 M of spending on assets, free cash was −$119 M: it spent more than its operations brought in.

The profit and loss account shows what was earned. The cash-flow statement shows the cash that actually came in. Comparing operating cash flow with profit is one of the best checks that a profit is real.

Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year.

FY25: operating cash −$106 M against profit −$391 M

  • Operating cash −$106 M
  • Net profit −$391 M
  • Free cash −$119 M
FY25: operating cash −$106 M against profit −$391 M
QuarterOperating cashNet profitFree cash
FY21−$148 M−$407 M−$155 M
FY22−$131 M−$107 M−$146 M
FY23−$156 M−$263 M−$172 M
FY24−$57.8 M−$260 M−$71.0 M
FY25−$106 M−$391 M−$119 M
Operating cash flow and net profit each year, $ M. The line is free cash flow: operating cash minus spending on assets. 5-year window, yearly figures.

Jun 2026: operating cash −$57.3 M = −319% of the quarter's profit

  • Operating cash (quarterly) −$57.3 M
Jun 2026: operating cash −$57.3 M = −319% of the quarter's profit
QuarterOperating cash (quarterly)
Mar 2023−$60.8 M
Sep 2023−$13.0 M
Dec 2023−$61.2 M
Mar 2024−$47.8 M
Jun 2024−$18.7 M
Sep 2024−$7.7 M
Dec 2024$16.4 M
Mar 2025−$32.0 M
Jun 2025−$35.1 M
Dec 2025−$20.5 M
Mar 2026$23.7 M
Jun 2026−$57.3 M

Operating cash as % of profit

  • Operating cash as % of profit −319%
Operating cash as % of profit
QuarterOperating cash as % of profit
Mar 2023−381%
Sep 2023–
Dec 2023–
Mar 2024–
Jun 2024–
Sep 2024–
Dec 2024–
Mar 2025−264%
Jun 2025–
Dec 2025–
Mar 202649%
Jun 2026−319%
Top: operating cash each quarter, $ M. Below: operating cash as a % of net profit; 100% means all of the quarter's profit came in as cash. Last 12 quarters.

What to look at next: the main use of cash is spending on assets. The next section checks what that spending is building.

Where does agilon health's cash go?

agilon health, inc. does not report the customer, stock and supplier day counts a cash cycle needs, so this section looks at its spending on assets instead. It spent $42.3 M on assets over the last 3 years. Averaged over those years that is 0.2% of FY25 revenue a year.

Working capital is the cash tied up between paying suppliers and getting paid. Debtor days: how long customers take to pay. Inventory days: how long stock sits. The cash cycle: the whole loop, in days of sales.

Nothing is estimated in place of the missing day counts, so no cash-cycle chart is drawn.

Spending on assets: $42.3 M over the last 3 years.

FY25: capex $13.2 M, steady spending

  • Capex $13.2 M
FY25: capex $13.2 M, steady spending
QuarterCapex
FY21$6.6 M
FY22$15.4 M
FY23$15.8 M
FY24$13.3 M
FY25$13.2 M
Capital spending each year, $ M.

Jun 2026: capex $3.4 M in the quarter

  • Capex (quarterly) $3.4 M
Jun 2026: capex $3.4 M in the quarter
QuarterCapex (quarterly)
Mar 2023$3.7 M
Sep 2023$4.1 M
Dec 2023$3.9 M
Mar 2024$3.1 M
Jun 2024$3.3 M
Sep 2024$3.5 M
Dec 2024$3.3 M
Mar 2025$3.8 M
Jun 2025$3.3 M
Dec 2025$3.0 M
Mar 2026$3.1 M
Jun 2026$3.4 M

Free cash

  • Free cash −$60.7 M
Free cash
QuarterFree cash
Mar 2023−$64.5 M
Sep 2023−$17.1 M
Dec 2023−$65.1 M
Mar 2024−$50.9 M
Jun 2024−$22.0 M
Sep 2024−$11.2 M
Dec 2024$13.2 M
Mar 2025−$35.8 M
Jun 2025−$38.3 M
Dec 2025−$23.5 M
Mar 2026$20.6 M
Jun 2026−$60.7 M
Top: capital spending each quarter, $ M. Below: free cash flow, $ M. Last 12 quarters.

In short: most of the cash goes on covering the loss, not on new assets; spending on assets is small next to it.

What is agilon health's P/E ratio, and how does it compare with its own history?

agilon health, inc. has no P/E right now, because its earnings are negative. The revenue and margin sections are where a turn would show first. Measured against sales instead, the market values agilon health, inc. at 0.3× its FY25 revenue of $5.9 B. The P/E comes back here once profit turns positive.

P/E is the share price divided by a year's profit per share: how many dollars the market pays for each dollar of yearly profit.

—P/E · earnings negative
n/mPEG · cannot be worked out, because 3-year earnings growth is not available

Is the agilon health business getting better or worse?

agilon health, inc.'s business trend cannot be read yet. There are fewer than eight usable quarters of growth figures, so there is not enough history to read the trend. This is based on 12 quarters of 2 measures, with some gaps.

Every business is somewhere on a path of getting better or worse, and this section names where. The last 12 quarters of growth in revenue, profit and earnings per share, plus the return the business earns on its capital, are read as lines. Getting worse: the lines are falling. Turning around: a low point has just formed and the last few quarters are rising from it. Getting better: the rise from the low has lasted. Growing steadily: steady growth with healthy returns. Slowing from a peak: still high, but slowing. When the lines disagree the result is mixed; too little history means no reading. CAGR (compound annual growth rate) is the steady yearly rate that would turn the starting value into the latest one. It is the fairest way to compare growth over different periods. If the 1-year figure is much bigger than the 10-year one, recent growth is running faster than the long-run trend. A dash means there is no figure for that period, or the starting year was a loss, where a growth rate means nothing.

Growth year by year: revenue −2.1% in FY25

  • Revenue growth −2.1%
Growth year by year: revenue −2.1% in FY25
QuarterRevenue growth
FY21–
FY2257%
FY2380.7%
FY2440.4%
FY25−2.1%
Growth on the year before, each year, %. Top: revenue. Zero line drawn.

Three growth lines over twelve quarters: revenue rolling over

  • Revenue 0.3%
Three growth lines over twelve quarters: revenue rolling over
QuarterRevenue
Sep 202376.2%
Dec 202374%
Mar 202458.4%
Jun 202451.4%
Sep 202441.4%
Dec 202440.4%
Mar 202523.1%
Jun 202511.8%
Sep 20255.2%
Dec 2025−2.1%
Mar 2026−2.8%
Jun 20260.3%

Profit

  • Profit 300%
Profit
QuarterProfit
Sep 2023–
Dec 2023–
Mar 2024−137.8%
Jun 2024–
Sep 2024–
Dec 2024–
Mar 2025–
Jun 2025–
Sep 2025–
Dec 2025–
Mar 2026300%
Jun 2026–
Growth on a year earlier, % at each quarter end. Top: revenue. Below: profit and earnings per share, on their own scale because they swing much more. Each is measured over the last 12 months. Where the 12-month history is short, the line uses single-quarter growth instead, which is noisier; extreme jumps from a tiny base are evened out before reading. Extreme jumps from a tiny base are drawn at the edge (▲). A gap means there is no reading for that quarter.

ROCE: the return line, worked out each quarter

  • ROCE −68.4%
ROCE: the return line, worked out each quarter
QuarterROCE
Sep 2023−8.7%
Dec 2023−23.5%
Mar 2024−23.9%
Jun 2024−28.4%
Sep 2024–
Dec 2024–
Mar 2025–
Jun 2025–
Sep 2025–
Dec 2025–
Mar 2026–
Jun 2026−68.4%
Operating profit over the last 12 months (before interest and tax) as a share of average capital employed (total assets minus current liabilities), %.
RecoveringRevenue growth · latest +0.3%, range −2.8% to +76.2%
FallingROCE · latest −68.4%, range −68.4% to −8.7%

Why it matters: with too little history, we say so rather than guess a direction.

One or more growth lines have an extreme jump caused by comparing with a near-zero or loss-making quarter. Those jumps are capped before reading and drawn at the edge of the chart, so one odd quarter does not decide the result.

There are fewer than eight usable quarters, so this page does not guess a direction from so little history.

Compound annual growth rate (%)

Compound annual growth rate over each period, %. Revenue, profit and EPS come from yearly figures; the stock price row is price growth over the same periods. A dash means no figure for that period, or the starting year was a loss.

Compound annual growth rate (%)
Measure1yr3yr5yr10yr
Revenue−2.1%+35.4%——
Stock price+476.9%−36.0%−31.2%—
+7.2%Revenue growth (Jun 2026) · latest quarter against a year ago
40.5%Revenue, 4 years · yearly growth over the long run

How much does agilon health earn on its capital?

agilon health, inc. earned a ROE of −309% in FY25. Its return on capital used (ROIC) is 42.6 percentage points below its cost of capital, so growth here does not yet pay for the capital it uses. It comes from a −6.6% net margin and 4.67× asset turnover (sales divided by assets).

Return on equity (ROE) is the profit the business earns on its shareholders’ money. We do not have the full capital split, so ROE is the longest history we can draw here.

Why the return is what it is (FY25): a −6.6% net margin × 4.67× asset turnover × 10.03× leverage (assets divided by equity) ≈ −309.1% on equity. The margin does its share; borrowing is a big part of it.

The key test, return on capital used minus the cost of capital: −21.3% − 21.3% = −42.6 percentage points. The 21.3% is an estimate of this company's own cost of capital. Read the sign and size of the gap, not the decimals. Negative: growth at these returns loses value until returns improve.

FY25: ROE −309%, the full history

  • ROE −308.8%
  • Cost of capital 21.3%
FY25: ROE −309%, the full history
QuarterROECost of capital
FY21−37.3%21.3%
FY22−10.3%21.3%
FY23−39.8%21.3%
FY24−55.2%21.3%
FY25−308.8%21.3%
Return on equity each year, % (line). 5-year window, low years included. The flat line is the 21.3% cost of capital used on this page.

Dec 2025: ROIC −163.4% (last 12 months) against a 21.3% cost of capital

  • ROIC (12 months) −163.4%
  • ROE (12 months) 77.7%
  • Cost of capital 21.3%
Dec 2025: ROIC −163.4% (last 12 months) against a 21.3% cost of capital
QuarterROIC (12 months)ROE (12 months)Cost of capital
Sep 2023−8.7%−6.5%21.3%
Dec 2023−11.1%−10.1%21.3%
Mar 2024−56.9%−87.2%21.3%
Jun 2024−1.8%1.9%21.3%
Sep 2024−13.3%−18%21.3%
Dec 2024−48.3%−74.5%21.3%
Mar 2025−61.9%−81.4%21.3%
Jun 2025−15%−1.6%21.3%
Sep 2025−77.7%−91.8%21.3%
Dec 2025−163.4%−123.3%21.3%
Mar 2026–−349.1%21.3%
Jun 2026–77.7%21.3%
ROIC and ROE over the last 12 months, each quarter, %; the flat line is the cost of capital. Last 12 quarters, lined up with the yearly figure.

Does agilon health have too much debt?

agilon health, inc. has total debt of $33.4 M against shareholder equity of $228 M as of Jun 2026, so its debt is 0.15× its equity, which is very little. Year by year, that ratio went from 0.05 in FY21 to 0.29 in FY25. So the returns on this page come from the business, not from borrowed money.

Debt-to-equity shows how much of the business is paid for with borrowed money. Lower is safer, and the direction matters as much as the level.

FY25: debt $36.8 M, 0.29× equity

  • Total debt $36.8 M
FY25: debt $36.8 M, 0.29× equity
QuarterTotal debt
FY21$59.6 M
FY22$56.0 M
FY23$46.1 M
FY24$41.5 M
FY25$36.8 M

Debt-to-equity

  • Debt-to-equity 0.29×
Debt-to-equity
QuarterDebt-to-equity
FY210.05×
FY220.05×
FY230.07×
FY240.09×
FY250.29×
Top: total debt each year, $ M. Below: debt-to-equity, ×. 5-year window.

Jun 2026: debt $33.4 M, debt-to-equity 0.15

  • Total debt (quarterly) $33.4 M
Jun 2026: debt $33.4 M, debt-to-equity 0.15
QuarterTotal debt (quarterly)
Sep 2023$51.8 M
Dec 2023$46.1 M
Mar 2024$48.0 M
Jun 2024$46.2 M
Sep 2024$43.9 M
Dec 2024$41.5 M
Mar 2025$42.0 M
Jun 2025$41.4 M
Sep 2025$37.1 M
Dec 2025$36.8 M
Mar 2026$33.4 M
Jun 2026$33.4 M

Debt-to-equity

  • Debt-to-equity 0.15×
Debt-to-equity
QuarterDebt-to-equity
Sep 20230.06×
Dec 20230.07×
Mar 20240.07×
Jun 20240.07×
Sep 20240.08×
Dec 20240.09×
Mar 20250.08×
Jun 20250.10×
Sep 20250.12×
Dec 20250.29×
Mar 20260.18×
Jun 20260.15×
Top: total debt each quarter, $ M. Below: debt-to-equity, ×. Last 12 quarters.

What is the agilon health shareholding pattern?

8.2% of agilon health, inc.'s tradable shares are in short positions, which are bets that the price will fall, so some traders are betting against it. At normal trading volumes, closing those positions would take about 3.9 days. US companies do not publish a quarter-by-quarter list of owners, so this page uses short interest instead.

There is no quarter-by-quarter list of owners here, so we look at short interest: the share of tradable shares held in short positions, which gain if the price falls.

It is a single reading at one point in time; we do not have its history.

8.2%Short interest · of the tradable float
3.9Days to cover · at typical volumes

Why it is at this level: the figure does not say who has the short positions or why, so we show the level without guessing the story.

How far is agilon health from balance-sheet trouble?

For agilon health, inc., the Z-score is 1.85. A Z-score above about 3 is safe and below about 1.8 signals danger, so this is in the grey area between the two. It estimates how far the balance sheet is from trouble; it is not a forecast of failure.

The Z-score estimates how far a company is from balance-sheet trouble. Above about 3 is safe; below about 1.8 is the danger zone. It was built for manufacturers, so it is not used for banks and lenders.

Why it matters: a Z-score of 1.85 is in the grey area, neither clearly safe nor clearly in trouble.

How does agilon health rank in its industry?

41.3 out of 100, rank 23 of 30 in Medical Care Facilities, with 64% of the evidence available.

agilon health, inc. scores 41.3 out of 100 against the 30 companies it is compared with in Medical Care Facilities, ranking 23. Relative strength against the index is 61.7%, and revenue and profit growth are weak.

The four parts add up to the total exactly: 13 + 3.5 + 11.1 + 13.7 = 41.3. This is the same number shown on the industry page; it is worked out once for the whole group and read here.

What would change it: The score would fall if profit growth turns negative or margins stop improving while the share price lags its sector.

Which companies is agilon health compared with?

agilon health ranks 23 of 30 Medical Care Facilities companies on the 4-Factor Sector Score, with 41.3 out of 100.

  1. 1Concentra Group Holdings Parent, Inc.CON · leader · Most evidence points up · 81% evidence71.9out of 100GrowthCapitalValuationRelative
    How the score adds upGrowth & earnings 24.0/35 · Revenue 14% · Profit 32.6% · Operating margin change 2.3 points · 83% evidenceCapital efficiency 16.6/25 · ROCE 14.5% · Operating margin 19.3% · 76% evidenceValuation 12.8/20 · P/E 19.5× · PEG 0.65 · 65% evidenceRelative strength 18.5/20 · Lead over its industry 20.3% · Lead over S&P 500 51% · 1 year 125.2% · 100% evidence · 12 of 12 weeks aheadExact sum: 24 + 16.6 + 12.8 + 18.5 = 71.9 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks.
  2. 2Nutex Health Inc.NUTX · leader · Most evidence points up · 64% evidence66.6out of 100GrowthCapitalValuationRelative
    How the score adds upGrowth & earnings 22.5/35 · Revenue 6.8% · Profit 100% · Operating margin change 44 points · 62% evidenceCapital efficiency 18.7/25 · ROCE 56.8% · Operating margin 57.8% · 76% evidenceValuation 10.8/20 · P/E 6.5× · PEG — · 15% evidenceRelative strength 14.6/20 · Lead over its industry 1% · Lead over S&P 500 28% · 1 year 79% · 100% evidence · 12 of 12 weeks aheadExact sum: 22.5 + 18.7 + 10.8 + 14.6 = 66.6 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer.
  3. 3Tenet Healthcare CorporationTHC · leader · Most evidence points up · 81% evidence65.7out of 100GrowthCapitalValuationRelative
    How the score adds upGrowth & earnings 20.8/35 · Revenue 5.4% · Profit 32.4% · Operating margin change 2.1 points · 83% evidenceCapital efficiency 17.1/25 · ROCE 15% · Operating margin 18.2% · 76% evidenceValuation 15.2/20 · P/E 7.2× · PEG 0.35 · 65% evidenceRelative strength 12.6/20 · Lead over its industry -1.3% · Lead over S&P 500 25.8% · 1 year 42.4% · 100% evidence · 12 of 12 weeks aheadExact sum: 20.8 + 17.1 + 15.2 + 12.6 = 65.7 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer.
  4. 4AMN Healthcare Services, Inc.AMN · breaking out · Evidence leans up · 64% evidence64.1out of 100GrowthCapitalValuationRelative
    How the score adds upGrowth & earnings 25.4/35 · Revenue 23.9% · Profit — · Operating margin change 3.4 points · 62% evidenceCapital efficiency 9.1/25 · ROCE 10.1% · Operating margin 4% · 76% evidenceValuation 10.3/20 · P/E 12× · PEG — · 15% evidenceRelative strength 19.3/20 · Lead over its industry 36.3% · Lead over S&P 500 69.4% · 1 year 167.2% · 100% evidence · 9 of 12 weeks aheadExact sum: 25.4 + 9.1 + 10.3 + 19.3 = 64.1 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer.
  5. 5Pediatrix Medical Group, Inc.MD · turning · Evidence leans up · 81% evidence61.9out of 100GrowthCapitalValuationRelative
    How the score adds upGrowth & earnings 19.1/35 · Revenue 0.6% · Profit 61.5% · Operating margin change -0.2 points · 83% evidenceCapital efficiency 14.6/25 · ROCE 14.8% · Operating margin 13.4% · 76% evidenceValuation 12.8/20 · P/E 11.6× · PEG 0.8 · 65% evidenceRelative strength 15.4/20 · Lead over its industry 1.6% · Lead over S&P 500 29.5% · 1 year 49.6% · 100% evidence · 8 of 12 weeks aheadExact sum: 19.1 + 14.6 + 12.8 + 15.4 = 61.9 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer.
  6. 6Healthcare Services Group, Inc.HCSG · turning · Evidence leans up · 85% evidence60.3out of 100GrowthCapitalValuationRelative
    How the score adds upGrowth & earnings 20.4/35 · Revenue 4% · Profit 100% · Operating margin change -3.2 points · 95% evidenceCapital efficiency 14.6/25 · ROCE 17.7% · Operating margin 6.7% · 76% evidenceValuation 14.3/20 · P/E 13.4× · PEG 0.43 · 65% evidenceRelative strength 11.0/20 · Lead over its industry -7.3% · Lead over S&P 500 18.3% · 1 year 53.8% · 100% evidence · 4 of 12 weeks aheadExact sum: 20.4 + 14.6 + 14.3 + 11 = 60.3 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer.
  7. 7Aveanna Healthcare Holdings Inc.AVAH · leader · Too little evidence to rank firmly · 58% evidence60.0out of 100GrowthCapitalValuationRelative
    How the score adds upGrowth & earnings 15.4/35 · Revenue — · Profit — · Operating margin change 1.6 points · 45% evidenceCapital efficiency 15.4/25 · ROCE 17.7% · Operating margin 12.6% · 76% evidenceValuation 10.6/20 · P/E 7.2× · PEG — · 15% evidenceRelative strength 18.6/20 · Lead over its industry 14.8% · Lead over S&P 500 45.2% · 1 year 62.6% · 100% evidence · 12 of 12 weeks aheadExact sum: 15.4 + 15.4 + 10.6 + 18.6 = 60 · What this means: Some evidence is missing, so the score is pulled toward the middle on purpose.
  8. 8Encompass Health CorporationEHC · leader · Evidence leans up · 81% evidence59.4out of 100GrowthCapitalValuationRelative
    How the score adds upGrowth & earnings 17.5/35 · Revenue 9.5% · Profit 20.2% · Operating margin change 0.3 points · 83% evidenceCapital efficiency 18.1/25 · ROCE 17% · Operating margin 18.1% · 76% evidenceValuation 12.2/20 · P/E 16.2× · PEG 0.8 · 65% evidenceRelative strength 11.6/20 · Lead over its industry -6.7% · Lead over S&P 500 19.5% · 1 year 22.3% · 100% evidence · 12 of 12 weeks aheadExact sum: 17.5 + 18.1 + 12.2 + 11.6 = 59.4 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer.
  9. 9HCA Healthcare, Inc.HCA · breaking out · Evidence leans up · 81% evidence58.3out of 100GrowthCapitalValuationRelative
    How the score adds upGrowth & earnings 15.4/35 · Revenue 7.3% · Profit 14.6% · Operating margin change -0.7 points · 83% evidenceCapital efficiency 19.9/25 · ROCE 26.3% · Operating margin 15.2% · 76% evidenceValuation 14.2/20 · P/E 12.6× · PEG 0.49 · 65% evidenceRelative strength 8.8/20 · Lead over its industry -18.7% · Lead over S&P 500 5.4% · 1 year 7.2% · 100% evidence · 10 of 12 weeks aheadExact sum: 15.4 + 19.9 + 14.2 + 8.8 = 58.3 · What this means: The valuation scores well, but earnings are not improving yet, so the business does not back up the low multiple so far.
  10. 10Universal Health Services, Inc.UHS · breaking out · Evidence leans up · 81% evidence57.7out of 100GrowthCapitalValuationRelative
    How the score adds upGrowth & earnings 18.8/35 · Revenue 10% · Profit 21% · Operating margin change -0.6 points · 83% evidenceCapital efficiency 16.4/25 · ROCE 16.3% · Operating margin 11.1% · 76% evidenceValuation 15.9/20 · P/E 5.9× · PEG 0.2 · 65% evidenceRelative strength 6.6/20 · Lead over its industry -24.5% · Lead over S&P 500 -1.6% · 1 year -14.3% · 100% evidence · 11 of 12 weeks aheadExact sum: 18.8 + 16.4 + 15.9 + 6.6 = 57.7 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer.
  11. 11LifeStance Health Group, Inc.LFST · turning · Evidence leans up · 64% evidence56.1out of 100GrowthCapitalValuationRelative
  12. 12Addus HomeCare CorporationADUS · turning · Evidence leans up · 81% evidence55.6out of 100GrowthCapitalValuationRelative
  13. 13PACS Group, Inc.PACS · turning · Evidence leans up · 71% evidence53.5out of 100GrowthCapitalValuationRelative
  14. 14National HealthCare CorporationNHC · quiet · Evidence leans up · 81% evidence53.1out of 100GrowthCapitalValuationRelative
  15. 15Fresenius Medical Care AGFMS · basing · Evidence leans up · 81% evidence50.7out of 100GrowthCapitalValuationRelative
  16. 16Guardian Pharmacy Services, Inc.GRDN · quiet · Evidence leans down · 64% evidence49.3out of 100GrowthCapitalValuationRelative
  17. 17Chemed CorporationCHE · turning · Evidence leans down · 81% evidence48.5out of 100GrowthCapitalValuationRelative
  18. 18Astrana Health, Inc.ASTH · turning · Evidence leans down · 81% evidence48.1out of 100GrowthCapitalValuationRelative
  19. 19Surgery Partners, Inc.SGRY · turning · Evidence leans down · 64% evidence48.1out of 100GrowthCapitalValuationRelative
  20. 20DaVita Inc.DVA · turning · Evidence leans down · 81% evidence47.9out of 100GrowthCapitalValuationRelative
  21. 21The Pennant Group, Inc.PNTG · turning · Evidence leans down · 81% evidence44.1out of 100GrowthCapitalValuationRelative
  22. 22The Ensign Group, Inc.ENSG · turning · Evidence leans down · 81% evidence41.8out of 100GrowthCapitalValuationRelative
  23. 23agilon health, inc. this pageAGL · turning · Evidence leans down · 64% evidence41.3out of 100GrowthCapitalValuationRelative
    How the score adds upGrowth & earnings 13.0/35 · Revenue 0.3% · Profit — · Operating margin change 9.6 points · 62% evidenceCapital efficiency 3.5/25 · ROCE -91.1% · Operating margin 1.3% · 76% evidenceValuation 11.1/20 · P/E -7.7× · PEG — · 15% evidenceRelative strength 13.7/20 · Lead over its industry 34.5% · Lead over S&P 500 61.7% · 1 year 476.9% · 100% evidence · 1 of 12 weeks aheadExact sum: 13 + 3.5 + 11.1 + 13.7 = 41.3 · What this means: Relative strength against the index is 61.7%, and revenue and profit growth are weak.
  24. 24InnovAge Holding Corp.INNV · quiet · Evidence leans down · 64% evidence39.9out of 100GrowthCapitalValuationRelative
  25. 25Acadia Healthcare Company, Inc.ACHC · turning · Evidence leans down · 71% evidence39.4out of 100GrowthCapitalValuationRelative
  26. 26Option Care Health, Inc.OPCH · breaking out · Evidence leans down · 81% evidence39.3out of 100GrowthCapitalValuationRelative
  27. 27Ardent Health, Inc.ARDT · breaking out · Evidence leans down · 71% evidence37.8out of 100GrowthCapitalValuationRelative
  28. 28Sonida Senior Living, Inc.SNDA · quiet · Evidence leans down · 64% evidence36.8out of 100GrowthCapitalValuationRelative
  29. 29Brookdale Senior Living Inc.BKD · quiet · Most evidence points down · 64% evidence32.9out of 100GrowthCapitalValuationRelative
  30. 30Select Medical Holdings CorporationSEM · Too little evidence to rank firmly · 36% evidence50.6out of 100GrowthCapitalValuationRelative

Missing figures are not scored as bad. They lower the confidence and pull the final score toward the middle. Relative strength counts only when the company has a reading for this week; with no reading, that factor is left out and its 20 points are shared across the other three in proportion. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led S&P 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step path the industry is placed on (basing, turning, breaking out, leader, fading, asleep), read from how many weeks running it has led S&P 500 and whether that lead is growing or shrinking. It describes where the share price stands, not the direction of earnings, and it is not a recommendation; it is left blank for a company whose weekly history is too short or too stale to read.

The figures in this ranking come from the industry comparison: results through the Sep 2026 quarter, and the P/E at that quarter's end. The sections above use the latest weekly price, so a P/E or return there can differ a little from the one here. The stage words in this ranking (such as losing its lead or breaking out) describe the lead over the index, not the price phase in the price section.

Related companies: Medical Care Facilities, all 30 compared on one page.

Which companies are close to agilon health in size?

agilon health is the 27th largest of 38 Medical Care Facilities companies on Sector Alpha by market value (scores of 4 November 2026). Just above it: Ardent Health, Inc., Healthcare Services Group, Inc. and Sonida Senior Living, Inc. Just below it: The Pennant Group, Inc., Nutex Health Inc. and InnovAge Holding Corp.

Medical Care Facilities companies close in size

  1. Ardent Health, Inc. $1.8 billion
  2. Healthcare Services Group, Inc. $1.8 billion
  3. Sonida Senior Living, Inc. $1.8 billion
  4. agilon health, inc. $1.6 billion
  5. The Pennant Group, Inc. $1.5 billion
  6. Nutex Health Inc. $1.4 billion
  7. InnovAge Holding Corp. $1.3 billion

All 38 Medical Care Facilities companies, largest first

Companies close in size in other industries

  1. Genesis Energy, L.P. $1.6 billion · Oil & Gas Midstream
  2. Distribution Solutions Group, Inc. $1.6 billion · Industrial Distribution
  3. agilon health, inc. $1.6 billion
  4. Photronics, Inc. $1.6 billion · Semiconductor Equipment & Materials
  5. Century Communities, Inc. $1.6 billion · Real Estate - Development

What else do people ask about agilon health?

What were agilon health's latest quarterly results?

agilon health, inc. reported revenue of $1.5 B and net profit of $18.0 M for the Jun 2026 quarter. Earnings per share were $1.04. The operating margin was 1.3%, 9.6 percentage points higher than a year earlier (as of 4 November 2026).

What is agilon health's market cap?

agilon health, inc.'s market capitalisation is $1.6 B at a stock price of $96.23. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 4 November 2026).

How is agilon health performing?

agilon health, inc.'s share price has been rising for 13 weeks. Over the past 13 weeks it has done better than the S&P 500, for 1 week running. This describes what the data did, not a rating (as of 4 November 2026).

Will agilon health's stock price go up?

This page does not forecast agilon health, inc.'s stock price. What it shows instead: the stock price is $96.23, and it has been rising for 13 weeks. Nobody can reliably say which way a price will move, and this site does not try (as of 4 November 2026).

Does agilon health have too much debt?

No, agilon health, inc. has little debt: its debt is 0.11× its equity. A year-by-year history of its borrowings is not in our data, so this uses the latest reading. So the returns on this page come from the business, not borrowed money (as of 4 November 2026).

Where is agilon health in its business cycle?

agilon health, inc.'s FY25 operating margin was −7.1%, against a 5-year range of −24.1% to −4.3%: the middle of its own range, neither a peak nor a low. The latest quarter was 1.3%.

Comparing margins with a company's own long history is a good way to see where it is in its cycle (as of 4 November 2026).

What could break the agilon health story?

Biggest thing to watch: the price has already been rising for 13 weeks, so timing is the risk more than the business.

On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 4 November 2026).

Is agilon health a stock worth studying right now?

What the numbers show: agilon health, inc.'s share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. The main open question: the next one or two quarters of results.

Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 4 November 2026).

Where do these numbers come from?

Sector Alpha, written by code from the published numbers. Data as of 4 November 2026.

Every chart on this page is drawn by code from the published figures, with no forecasts and no price opinions.

See the plain-text version of this page.

More lists

Every Sector Alpha list, grouped

X · Instagram · YouTube · About · Newsletter · Newsletter archive
This is research, not advice. We’re not SEBI-registered.